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1. Introduction 
Liver transplantation similar to other allograft transplants requires the use of 
immunossupressive therapy to avoid graft rejection in the host. Immunossupressive drugs 
can also decrease the capacity of the host immune system to response against infectious 
agents which would not be a problem to immunocompetent persons. Many infectious 
agents such as bacteria, fungus, protozoa and viruses can cause serious complication in the 
post-transplant course (Blair & Shimon, 2005). 
Several different viruses have been studied at long of the time and these studies have 
demonstrated that herpesviruses can be important infectious agents and affects the 
management of the liver transplant recipients (Kotton, 2010).  
Herpesviruses belong to the Herpesviridae family (Hudnall et al., 2008), and have been 
isolated eight different types of these viruses (Table 1). The human herpesvirus simples type 
I and type II (HSV-1 and HSV-2), are usually associated with labial and genital herpes, 
respectively. However, genital herpes can be a consequence of HSV-1 infection and labial 
herpes can also be caused by HSV-2. The human herpesvirus type 3 (varicella-zoster) causes 
chickenpox, especially in children, and re-infection or reactivation, may be the cause of the 
appearance of zoster. Human herpesvirus type 4 (Epstein-Barr virus) is associated with 
infectious mononucleosis syndrome, Burkitt's lymphoma and nasopharyngeal carcinoma. 
The human herpesvirus type 8 is associated with Kaposi's sarcoma, and can cause death in 
immunosuppressed individuals, especially in acquired immunodeficiency syndrome 
(HIV/AIDS). 
Cytomegalovirus (CMV), Human Herpesvirus 6 (HHV-6) and Human Herpesvirus 7 (HHV-7) 
are DNA viruses, members of the betaherpesvirinae subfamily of the Betaherpesviridae (Tong et 
al., 2000). Cytomegalovirus primary infection causes ‘mononucleosis like syndrome’ and 
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HHV-6 and HHV-7 primary infections cause common febrile infectious syndromes in early 
childhood, known as exanthem subitum and roseola.  
Virus Synonymous Sub-family Abbreviation 
Human herpesvirus -1 Herpes simplex-1 α HSV-1/HHV-1 
Human herpesvirus -2 Herpes simplex-2 α HSV-2/HHV-2 
Human herpesvirus -3 Varicella-zoster α VZV/HHV-3 
Human herpesvirus -4 Epstein-Barr γ EBV/HSV-4 
Human herpesvirus -5 Cytomegalovirus β CMV/HHV-5 
Human herpesvirus -6 None β HHV-6 
Human herpesvirus -7 None β HHV-7 
Human herpesvirus -8 None γ KSHV/HHV-8 
Table 1. Complete list of the human herpesviruses 
Betaherpesviruses are ubiquitous and seropositivity for these viruses can differ dependently 
of geographical region and other characteristics of the studied cohort. CMV seroprevalence 
is largely known around the world while HHV-6 and HHV-7 seroprevalences remain less 
studied. However, is estimated that HHV-6 and HHV-7 prevalences would also be high in 
the majority of the places.  
In immunocompetent individuals, beteherpesviral primary infections are usually self-
limiting although some cases of neurological manifestations have been described especially 
regarding HHV-6 in children (Donati et al., 2003; Matsumoto et al., 2011). It is not clear 
whether the neurological manifestation is caused by herpesviral brain tissue invasion or is 
an indirect effect of the infection.  
After primary infection, betaherpesviruses remain latent in the host and could reactivate 
sporadically leading to a transient viremia. Although some syndromes (e.g. chronic fatigue 
syndrome and multiple sclerosis) have been related to herpesviral reactivation, the role of 
the viruses in these syndromes remains unclear (Dewhurst, 2004).   
CMV, HHV-6 and HHV-7 can more frequently reactivate during immunosuppression 
following organ transplantation (Tong et al., 2000). CMV infection is known as major 
infectious complications after transplantation and has been considered an important cause 
of morbidity and mortality in bone marrow transplantation and solid organ transplant 
recipients. Although the role and impact of CMV infection on the post-transplant course is 
well characterized, the other two members of the betaherpesviruses family have been 
acknowledged only recently.  
1.1 Cytomegalovirus 
The diseases caused by CMV occur in underdeveloped and developing countries and the 
prevalence varies from 40 to 60% in the northern hemisphere countries, while in Africa and 
Latin America rates from 80 to 100% were observed (Suassuna et al., 1995; Costa et al., 1999). 
About 80% of the population between the late childhood and early adolescence is already 
infected by CMV (Almeida et al., 2001) and can harbor the virus in several body sites, 
especially in the salivary glands and different types of leukocytes. The peripheral blood 
mononuclear cells appear to be the most important site for CMV latency. 
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There are different variants or genetically distinct strains of CMV and therefore the cross-
protective immunity is considered partial (Ishibashi et al., 2006). The possibilities for the 
occurrence of a new exposure to another CMV strain are numerous. Immunosuppressed 
patients can be submitted to transfusions of blood components containing latent viruses, 
they may receive bone marrow or solid organs containing CMV and, in some cases, 
undergoing dialysis in equipment contaminated with viruses. It is for this reason that has 
been verified that the rate of cytomegalovirus infection/reinfection in these circumstances 
can be high (approximately 50%). 
In healthy adults, CMV is usually asymptomatic. Some individuals may have symptoms 
similar to infectious mononucleosis syndrome, such as lymphadenopathy, fever, rash, 
malaise, arthralgia, hepatomegaly and splenomegaly. In immunocompromised patients, 
CMV may modulate the immune response and leads to more complex clinical presentation 
including death, dependently of the situation involved. 
The American Society of Transplantation classified the presence of CMV in the body into 
two situations (Kotton et al., 2010). 
- CMV infection: evidence of CMV replication regardless of symptoms (different from 
latent CMV). 
- CMV disease: evidence of CMV infection associated with symptoms. CMV disease can 
be further categorized as a viral syndrome with fever, malaise, leukopenia, 
thrombocytopenia or as a tissue invasive disease. 
Whereas liver transplantation, epidemiological studies demonstrate a high incidence of 
CMV active infection. Some facts should be considered, for example, the previously infected 
patients who receive organs from donors with genotypically distinct latent viruses may 
develop a new infection. In addition, the surgical stress generated by the transplantation 
procedure may lead to a reactivation of latent CMV (Kotton et al., 2010). 
CMV disease is considered one of the most common complications after liver transplant 
recipients, with significant morbidity and mortality (Thomasini et al., 2007). Studies in the 
transplant series have shown that higher viral load values correlate with increased risk for 
development of disease. 
Thus, sensitive techniques were described in an attempt to identify earlier individuals who 
have higher risk to development of CMV disease with the goal to reduce the severity of the 
cases. The direct detection of the virus by conventional techniques, urine or saliva, is a 
procedure with limited clinical value. Moreover, it is technically difficult, expensive and 
provides results only after 3-5 weeks. Culture of CMV in blood or urine has low sensitivity. 
Culture of tissue samples is an option for confirmatory diagnosis of invasive diseases, 
especially in the case of gastrointestinal manifestations, in which, generally molecular and 
antigen-based diagnosis are negatives (Kotton et al., 2010). 
Before liver transplantation, serology for CMV can be used in both the organ donor and the 
recipient. A quantitative test for anti-CMV IgG should be used in combination with IgM test 
due to IgG serological tests are more specific than IgM tests. The serology of donor and 
recipient is the key to predicting the risk of infection. In the case of donor and recipient were 
sero-negative during the pre transplant, serology should be repeated at the time of 
transplantation, if there is a significant time between screening and transplantation. 
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However, recent blood transfusion could present false results in the serological tests. In 
patients after liver transplantation, serology has no role in diagnosis of active CMV disease.  
The detection of CMV antigen matrix (pp65) –antigenemia is a technique highly sensitive, 
rapid, quantitative, and with significant clinical correlation (van der Bij et al., 1988; Bonon et 
al., 2005). Patients who present positive results can be submitted to antiviral therapy and the 
response can be monitored periodically to demonstrate the efficacy of the treatment and the 
possibility of drug resistance. The limitation may be the definition of a limit of positivity 
(‘cut-off’) to start the treatment. Moreover, neutropenia can raise difficulties to perform this 
technique due to the fact that antigenemia requires a sufficient number of neutrophils to 
detect CMV viral antigen. CMV causes an abortive replication within neutrophils and leads 
to uptake of antigen in perinuclear area (Kas-Deelen et al., 2001) which can be detected by 
use of monoclonal antibodies against pp65-antigen. Either fluorescent or enzyme labelled 
conjugate can be used to reveal the reaction. However, enzyme labelled conjugate can be 
revealed by coloured reaction and dispenses the use of ultraviolet microscope. Figure 1 
shows positive pp65-antigenemia using enzyme labelled conjugate.  
 
Fig. 1. Nuclei of neutrophils stained in brown indicating positive pp65-atigenemia 
(counterstained with Harris´s hematoxylin). Mouse C10 and C11 monoclonals atibody 
against pp65-matrix CMV antigen and rabitt anti-mouse Ig horseradish peroxidase 
conjugate. The reaction was revealed by hydrogen peroxide and amino-ethyl-carbazole 
(Sampaio et al., 2011) 
Molecular techniques such as Polymerase Chain Reaction (PCR) and Nucleic Acid Sequence 
Based Amplification (NASBA) had gradually been incorporated in the laboratorial diagnosis 
of CMV.  
Whereas the viral biology, it is necessary to demonstrate the presence of viral mRNA, or 
portions of the viral genome expressed only in the replicative phase and not in latency. 
Using PCR the sensitivity of the PCR should be adjusted to detect only significant viral 
loads which could not easily performed. Unfortunately, due to very high sensitivity, 
molecular techniques may reveal positive results without relevant clinical features 
(Thomasini et al., 2007). In patients with higher risk level to progression of the CMV disease, 
such as liver transplantation, positive results in molecular tests can be an indicative to 
introduction to the preemptive therapy despite some of these patients not have clinical 
manifestation.  
www.intechopen.com
 
Betaherpesviruses in Adult Liver Transplant Recipients 
 
397 
Antigenemia has been considered to be less sensitive than molecular tests although has 
significant clinical correlation. In other hand, the molecular techniques are more sensitive, 
but may be dissociated of clinical manifestation in some situations. Thus, in patients at high 
risk (liver transplant recipients, CMV sero-negative patients who received organs from sero-
positive patients, patients who used mycophenolate or anti-OKT 3) would be benefited 
whether monitored by molecular techniques or by antigenemia relying on lower ‘cut-off’ 
levels. 
More recently, real-time PCR has been considered faster, very sensitive and provides more 
accurate discrimination than other molecular techniques. However, the establishment of the 
‘cut-off’ levels to discriminate between significant viral load and transient viremia is also 
necessary. Moreover, real-time PCR has been considered expensive and requires specialized 
staff. Either plasma or whole blood specimens can provide diagnosis and prognostic 
information regarding CMV disease. Qualitative PCR is an option for surveillance if this 
technique is the unique available option. The diagnosis of tissue invasive CMV disease, 
should be confirmed by immunohistochemistry or in situ DNA hybridization The decision 
regarding which test to use will depend on many factors including available resources, 
technical staff, patient population, volume of samples tested and cost (Kotton et al., 2010). 
The gold standard for treatment of CMV is intravenous ganciclovir, although oral 
valganciclovir is non inferior in nonlife-threatening disease. In patients with life-threatening 
CMV disease and in children, intravenous ganciclovir still the preferred drug, because data 
on the effect of oral treatment are limited. The treatment should be monitored weekly by 
viral loads and treating must continue until one or two consecutive negative samples are 
obtained, but not shorter than 2 weeks (Kotton et al., 2010). 
Universal prophylaxis involves the administration of antiviral drugs to overall of patients or 
a subset of “at risk” patients. Antiviral administration are usually started in the immediate 
or very early post transplant period and continued about 3 to 6 months. Several antivirals 
have been used, including acyclovir, valacyclovir intravenous ganciclovir, oral ganciclovir 
and valganciclovir. In the preemptive therapy, laboratory monitoring detects asymptomatic 
viral replication and antiviral therapy is initiated to prevent the progression to clinical 
disease. One of the major concerns with preemptive therapy is that it may not prevent the 
indirect effects on graft and patient survival. 
Dosing of antiviral medications should be based on standard recommended dosing 
algorithms (for patients with normal creatinine clearance: valganciclovir 900 mg once a day, 
intravenous ganciclovir 5 mg/kg once a day, or oral ganciclovir 1,000 mg three times a day) 
and carefully adjusted for renal function. 
Drug resistance in some CMV strain had been reported and this fact must be considered in 
non-responsive patients. Some studies have focused in genotyping of CMV which could 
indicate strains presenting resistance to conventional treatment. 
1.2 Human Herpesvirus 6 
In Brazil serological prevalence surveys conducted in North and Southeast regions show 
that antibodies against HHV-6 were present in 90% of the individuals among the studied 
population (0-40 years-old) with occurrence of the primary infection in the first years of life 
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(Freitas et al., 1997; Linhares et al., 1991). Reactivation of latent HHV-6 is common after  
liver transplantation, possibly induced and facilitated by allograft rejection and 
immunosuppressive therapy (Abdel et al., 2009; Griffths et al., 2000). HHV-6 may affect the 
success of the transplant procedure which is observed clinical findings as: fever, 
neutropenia, nervous central system manifestations or other visceral involvements 
(DesJardin et al., 2001). In addition, HHV-6 viremia is an independently significant 
predictive factor for invasive fungal infections and is associated with late mortality in liver 
transplantation recipients (Rogers et al., 2000). On the other hand, the rejection of the 
transplanted organ can also be enhanced when the patient is co-infected with CMV 
(Lautenschlager et al., 2000; Humar et al., 2000).  
The expression of different cellular antigens can be dramatically altered in HHV-6-infected 
tissues which the viral infection can induce to CD4 up regulation and CD3 down 
modulation in the T cells. HHV-6 can severely affect the physiology of secondary lymphoid 
organs through direct infection of T lymphocytes and modulation of key membrane 
receptors and chemokines (Grivel et al., 2003). Since the effects of HHV-6 in cellular immune 
system it could be affect the response against other infectious agents or facilitate the 
mechanism of graft rejection in the host. 
The diagnosis of reactivation or new infection by HHV-6 is not made easily. Serological 
techniques are available but the contribution of a positive result is limited by the high 
prevalence of infection in adults, as mentioned above (Freitas et al., 1997; Linhares et al., 
1991). The report of specific HHV-6 IgM in sera or a four-fold rise in IgG antibodies can be 
used as diagnostic criteria, but is not as sensitive as desired. Moreover, the interpretation of 
serological results is complicated by the fact that both primary and secondary infections 
with other herpes viruses may be associated with a concurrent antibody response to HHV-6 
(Osman et al., 1997). In addition, the presence of residual IgM against HHV-6 in the 
bloodstream can complicate the interpretation of the serological tests (Peigo et al., 2009).  
Antigenemia techniques to detect HHV-6 in blood have been described in the literature 
(Sampaio et al., 2011; Lautenschlager et al., 2002). Similar to pp65-atigenemia used for CMV, 
monoclonals antibodies against specific HHV-6 protein could be use with the purpose to 
detect only active infections. The antigenemia could be an alternative to molecular 
techniques because is a quantitative method and requires relatively few apparatus. HHV-6 
antigenemia, different from CMV, requires the use of purified lymphocytes to detect 
antigen. Positivity in peripheral monocytes occurs occasionally although lymphocytes are 
more frequently positive.  
Although the use of HHV-6 antigenemia could be promissory, the technique still needs 
improvements and establishment of ‘cut-off’ values to clinical use. Moreover, the sensitivity 
and specificity to detect HHV-6 active infection have been not completely studied.  
The techniques based on nuclei acid amplification are also available for the diagnosis of 
HHV-6 (Secchiero et al., 1995). However, the results obtained are controversial, because it 
depends on the PCR’s method employed (Shibata et al., 1992; Demmler et al., 1998).  
Since HHV-6 disease can be established, infection can be treated with intravenous 
ganciclovir, foscarnet, or cidofovir and this should be complemented by a reduction in 
immunosuppression (Razonable & Lautenschlager, 2010). The efficacy of acyclovir against 
HHV-6 infection seems to be lower than others. Moreover, foscarnet and cidofovir could be 
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more effective than ganciclovir against HHV-6 infection of astroglioma cells. Although 
ganciclovir and cidofovir are therapeutic options, on the basis of in vitro data and limited 
clinical experience reported in the literature, foscarnet is probably the preferred treatment 
for HHV-6 associated encephalitis.  
Patients could be treated with intravenous ganciclovir (2.5 mg/kg daily) for 3-6 weeks, 
cidofovir 5mg/kg once weekly for 2 consecutive weeks or intravenous foscarnet (40 mg/kg 
every 12 hours) for 3-4 weeks (Vinnard et al., 2009). However, in patients with renal failure, 
dose must be adjusted to avoid toxicity in the patients. In addition, viral monitoring is 
necessary (by PCR or antigenemia) to avoid interruption of the treatment prior 
disappearance of viremia.  
Similar to CMV, some strains of HHV-6 can present drug resistance and the strategies 
described above could also not have efficacy.  
1.3 Human Herpesvirus 7 
HHV-7 has been isolated from T-CD4+ cells purified from peripheral blood mononuclear 
cells of a healthy individual by Frenkel et al. (1990). HHV-7 like other betaherpesviruses 
remains latent or at low level of viral replication after primary infection or can reactivate 
during immunosuppressed states (Ihira et al., 2001). HHV-7 shares many properties of 
HHV-6, suggesting that the factors that control their reactivation or increased viral 
replication in immunosuppressed patients may be similar (Mendez et al., 2001). 
HHV-7 infects most specifically, T-CD4+ cells, which could result in cytotoxicity and 
mmunomodulatory activities (Secchiero et al., 2001). It has also been demonstrated that 
the down modulation of human leukocyte antigen (HLA) and beta-2-microglobulin 
expression by HHV-7 is linked to viral replication and is not merely the consequence of 
the interaction of virions with the cell surface. Infected cells can therefore efficiently 
escape from host immune pressure that might explain the persistence of HHV-7–positive 
cells in several types of tumors and chronic infectious diseases (Mirandola, 2006). 
Although HHV-7 has restricted tropism to CD4+ cells, it should be noted that HHV-7–
infected T-CD4+ cells kill uninfected T-CD8+ cells in vitro. Moreover, HLA class I and beta-
2-microglobulin are also down modulated in the T-CD8+ cells on the presence of HHV-7–
infected leukocytes in vitro (Secchiero et al., 2001). Similar to HHV-6, HHV-7 infection 
could modulate the host immune system enhancing the risk to graft rejection and other 
type of infections.   
Although in liver transplant recipients HHV-6 has been related to clinical consequences 
(Feldstein et al., 2003), the specific clinical syndrome spectrum of HHV-7 remains not 
clear (Ihira et al., 2001; Mendez et al., 2001). Several methods and different biological 
materials have been proposed to detect HHV-7 infection. Serological assays presents the 
same problems reported to HHV-6 and interpretation of these test are frequently difficult. 
Nested polymerase chain reaction (nested-PCR) using DNA extracted from either serum 
or plasma could detect only HHV-7 active infection (Ihira et al., 2001; Feldstein et al., 
2003).  
In our center, we found that nested-PCR carried out in DNA extracted from sera did not 
detect latent HHV-7 in a healthy cohort (Thomasini et al., 2008). In addition, positive IgM 
anti-HHV-7 and/or significant increase in IgG anti-HHV-7 titers were correlated with 
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positive nested-PCR for HHV-7 in adult liver transplant recipients (Peigo et al., 2009). 
However, many technical and clinical aspects remain to be clarified regarding these tests.  
Antigenemia can be performed to detected HHV-7 antigen in peripheral lymphocytes using 
similar technique describe to HHV-6 (Sampaio et al., 2011; Lautenschlager et al., 2002). 
HHV-7 antigen can be detected mainly in lymphocytes probably in T-CD4+ lymphocytes.  
The majority of HHV-7 infections do not require antiviral medication, but the severe 
complications could be treated with ganciclovir and its derivates or foscarnet and cidofovir 
(Ongrádi et al., 2010). 
There a few reports in the literature regarding treatment against HHV-7 infection probably 
due to fact that HHV-7 commonly causes not remarkable clinical outcomes.  However, 
studies have demonstrated that treatment based on ganclclovir or valganciclovir following 
the same protocol used to CMV can be effective against concomitant HHV-6 and HHV-7 
infection after lung and heart-lung transplantation (Lehto et al., 2007). Thus, the same 
protocol could hypothetically be used against HHV-7 in liver transplant patients. 
2. Experience of the State University of Campinas regarding 
betaherpesviruses in liver transplantation  
The aim of this study was to detect and to monitor CMV, HHV-6 and HHV-7 active 
infections in adult liver transplant recipients using nested-PCR and to describe the clinical 
aspects related to betaherpesviruses in these patients. 
2.1 Materials and methods 
Twenty-nine adult liver transplant patients (20 man and 9 woman), median age of 47 years 
(range 18 to 66), transplanted at the Liver Transplant Unit (University Hospital, State 
University of Campinas – Sao Paulo – Brazil) were included in this study.  
The basic immunosuppressive therapy consisted of cyclosporine (0.4 mg/kg/d), 
methylpredinisolone (1.0 g first month, 20 mg at 30 days decreasing to 5 mg/mo to 90 days), 
azathioprine (100mg/d). Mycophenolate mofetil (100 mg/d) and tracolimus (FK) (0.1 
mg/kg/d) were prescribed based on selected patient’s characteristics and specific protocol 
studies. Acyclovir (5 mg/kg per day for 2 months) was employed as antiviral prophylaxis to 
Herpes simplex.  
No routine CMV prophylaxis was used and ganciclovir (5mg/kg/d) for 6 weeks was 
administrated as treatment for symptomatic CMV patients. High doses of 
methylpredinisolone were used as antirejection treatment. Patient’s characteristics related to 
age, sex and underlying liver disease were summarized in Table 2. 
Peripheral blood was obtained from patients at the time of transplantation, as well as 
weekly for the first month and once a month to 180 days. Ethylenediamine tetraacetic acid 
(EDTA)-treated blood samples were used to DNA extraction from peripheral blood 
leukocytes (PBL) and serum (from without anticoagulant tube) of each blood sample was 
also separated by centrifugation. The obtained sera were then frozen (-20°C) until testing. 
The protocol was designed on accordance with the requirements for research involving 
human subjects in Brazil, and it was approved by the Institutional Ethics Committee. 
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2.1.1 CMV serological assay 
Anti-CMV IgG and IgM were tested in sera of the donors and patients before 
transplantation. Assays were carried out using ELISA-Commercial Kits (Sorin Diagnostics, 
Saluggia, Italy) following manufacture’s instructions.  
 
Patient´s Characteristics 
 
Median age (years) 47 (range: 18-66) 
Sex (male/female) 20/9 
 
Diagnosis of underlying liver disease 
 
Hepatitis C 15 
Alcoholic liver disease 3 
Hepatitis B 2 
Hepatitis C and alcohol 2 
Cryptogenic cirrhosis 2 
Hepatitis B and alcohol 1 
Primary biliary cirrhosis 1 
Autoimmune hepatitis 1 
Primary sclerosing cholangitis 1 
Hemochromatosis and alcohol 1 
Table 2. Demographic characteristics of the patients studied 
2.1.2 HHV-6 and -7 serological assays 
IgG and IgM antibodies against HHV-6 and HHV-7 were tested in sera of the donors and 
patients before transplantation by an indirect immunofluorescent assay. The standard HHV-
6 and HHV-7 antigens were prepared from viral culture of each virus (cord blood 
mononuclear cells infected by only one virus) and absence of cross-infectivity was 
confirmed by immunological or molecular methods. Infected cells were coated onto wells of 
immunofluorescence slides, air dried, and then fixed (cold methanol-acetone). The wells 
were covered with serial dilutions of patients’ sera (starting from a 1:10 dilution) and 
incubated for 1 h at 37°C. For IgM detection, a single dilution of 1:20 of each sample was 
carried out. Slides were washed 3 times with PBS, wells were covered with anti-human IgG 
or IgM fluorescent conjugate diluted PBS/Evans’s blue (Biomerieux Inc., Lyon, France), and 
then incubated for 1 h at 37°C.The slides were washed 3 times with PBS, buffered glycerin 
mounted, and immediately observed under an ultraviolet (UV) photo microscope (Leica 
DM2000,Wetzlar, Germany). All the samples were pre-treated with RFAb-sorbant (Hoescht-
Behring, Kanata, Ontario, Canada) to avoid interference of IgG and rheumatoid factor in the 
IgM immunofuorescent assay (Ihira et al., 2001; Ablashi et al., 1998). The antibody titer was 
defined as the reciprocal of the serum dilution showing specific fluorescence.  
2.1.3 Peripheral blood leukocyte (PBL) DNA extraction 
Briefly, PBL were lysed after separation following protocol previously described (Bonon et 
al., 2005). PBL DNA was precipitated with cold ethanol and then eluted in 50µL of TE-buffer 
(10mM Tris, 1mM EDTA) and stored frozen (-20°C) until PCR analysis. 
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2.1.4 Serum DNA extraction 
Briefly, DNA was extracted from 200 µL of serum using a phenol-chloroform protocol after 
incubation overnight in lysis buffer (10mM Tris-HCl pH 8.0, 10 mM EDTA, 10 mM NaCl, 
0.2% dodecyl sodium sulfate and 100 µg proteinase K) at 56ºC followed by DNA 
precipitation with cold ethanol. The resulting DNA pellet was eluted in 50µL of TE-buffer 
(10mM Tris, 1mM EDTA) and stored frozen (-20°C) until PCR analysis. 
2.1.5 CMV nested-PCR 
Five microliters of DNA extracted from PBL, as described above, were used in the nested-
PCR using reaction mixture containing specific primers to CMV following protocol 
previously described (Shibata et al.,1992; Demmler et al.,1998).  
2.1.6 HHV-6 and HHV-7 nested-PCR 
Nested-PCR was carried out for each virus using 5 μL of DNA, extracted from serum as 
described above. Primers and protocol used to HHV-6 nested-PCR were previously 
described by Secchiero et al. (1995). Primers and protocol used to HHV-7 nested-PCR were 
previously described by Pozo et al. (1999) with some modifications (originally a multiplex-
PCR).  
Amplifications were carried out on a Peltier Thermal Cycler - MJ Research (Watertown–MA-
USA).This The nested-PCR product was analyzed under UV light after electrophoresis in 2% 
agarose (Gibco-BRL) stained with ethidium bromide. All nested-PCR was carried out in 
duplicate using a second fresh aliquot. Polymerase chain reaction for beta-globin gene was 
carried out to detect contamination of serum with leukocytes and false negative results from 
incorrect DNA extraction from PBL. 
Positive and negative controls for each virus were included systematically. Genomes 
amplifications using the referred primers results in DNA fragments containing 159, 258 and 
122 base pairs of CMV, HHV-6 and HHV-7, respectively. Some nested-PCR products of each 
virus were sequenced analyzed and compared to the GenBank database using Software 
ChromasPro® (Thecnelysium Pty Ltd).  
2.1.7 Definitions 
CMV active infection was defined based on detection of CMV DNA in PBL by nested-PCR. 
HHV-6 and HHV-7 active infections were also defined based on detection of virus DNA in 
serum by nested-PCR. Transient viremia was defined when virus DNA was detectable only 
once or in no-consecutive samples.  
Latent infection, reinfection and reactivation were defined base on criteria proposed by 
Ljungman et al., 2002. Co-infections were defined when two or more viruses were detected 
in the same sample.  
Symptomatic CMV infection (‘CMV disease’) was divided into two situations: Tissue-
invasive disease and “CMV viral syndrome” (Kotton et al., 2010).  
Briefly, Tissue-invasive disease was defined based on symptoms consistent with CMV 
disease including fever, malaise, myalgia, anorexia and leukopenia accompanied of CMV 
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active infection and when biopsy proven CMV identification (Taber et al. 2004, Ljungman et 
al., 2002). “CMV hepatitis” and “CMV gastrointestinal disease” was diagnosed based on 
criteria proposed by Ljungman et al. (2002). “CMV viral syndrome” was defined based on 
unexplained fever (>37.5ºC) for at least 3 days, in combination with at least one of the 
following features: arthralgia, leukopenia (<3 x109/l), thrombocytopenia (<150x109/l), liver 
enzymes elevation (ALT>50 U/l). Asymptomatic CMV infection was defined when CMV 
active infection occurs without signs, symptoms, or laboratory abnormalities described 
above. 
Clinical symptoms such as fever, encephalitis, interstitial pneumonitis, hepatitis and 
laboratorial findings as leukopenia and thrombocytopenia were taken into account and 
CMV, HHV-6 and HHV-7 active infections were compared to these episodes. The 
laboratorial monitoring of graft function was based on elevation of serum alanine 
aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase and bilirrubins. 
Rejection episodes were documented based on histopathological analysis of the liver 
biopsies (Banffs schema). 
2.1.8 Statistical analysis 
The comparison of categorical variables was performed using Fisher’s exact test or chi-
squired test and Mann-Withney-U test for continuous variables. A p<0.05 was considered 
statistically significant. 
3. Results 
All patients and donors had positives anti-CMV, anti-HHV-6 and anti-HHV-7 IgG before 
transplantation (D+/R+), indicating that all of them patients were virus 
reactivations/reinfections. CMV DNA was detected in 20 (68.9%) of 29 patients, median 
time to first CMV detection was of 50 days (range 7 to181). HHV-6 DNA was detected in 13 
(44.8%) of 29 patients, median time to first HHV-6 detection was of 27 days (range 0 to 143). 
HHV-7 DNA was detected in 14 (48.2%) of 29 patients, median time to first HHV-7 detection 
was of 19 days (range 0 to 170). Six patients had HHV-7 DNA detectable already at the time 
of transplantation contrasting with two cases of HHV-6 and none of CMV. IgM against 
HHV-7 was detected in 100% of these patients who had detectable DNA already at the time 
of transplantation (P=0.002). Neither patient nor donor had positive IgM against CMV and 
HHV-6.  
The three viruses together were found in 6/29 (20.7%) patients but in none sample at the 
same time. Co-infections by CMV/HHV-6, CMV/HHV-7 and HHV6/HHV-7 occurred in 5 
(17.2%), 2 (6.9%) and 2 (6.9%) of the patients, respectively. Kinetic of the detection for three 
viruses was shown in Figure 2. 
The statistical analysis showed that the detection of CMV, HHV-6 and HHV-7 was 
independent of one another (P>0.05). Diagrams illustrating positive nested-PCR for any 
combination of betaherpesviruses were shown in Figure 3. 
Among the 20 patients with detectable CMV DNA, 10 (34.4% of total of the patients enrolled 
in this study) developed symptomatic CMV infections including “CMV viral syndrome” 
(n=5), CMV hepatitis (n=4) and CMV gastrointestinal disease (n=1). The symptoms have 
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occurred 16 days (average) after first CMV DNA detection. Considering the patients with no 
detectable CMV DNA in their blood, none had CMV disease. The relationship between the 
detection of CMV DNA and symptomatic CMV infection was considered statistically 
significant (P=0.009). HHV-6 was detected in 50% of the patients with symptomatic CMV 
infection and in 30% of the patients without symptoms (P=0.32). HHV-7 was also detected 
in 60% of the symptomatic CMV infection and in 70% of the patients with asymptomatic 
infection (P=0.50). Of 10 patients who had liver dysfunction, 7 (70%, P=0.006) had 
symptomatic CMV infection and 2 (20%) had only HHV-6 active infection at the time of 
dysfunction.  
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Fig. 2. Kinetic of detection for CMV, HHV-6 and HHV-7 in liver transplant recipients by 
nested-PCR 
Of 10 patients that had liver dysfunction, five presented episodes of graft rejection graded 
as mild. One was related to CMV hepatitis. One had symptomatic CMV/HHV-6 co-
infection (CMV hepatitis) 36 days prior rejection and one other had symptomatic 
CMV/HHV-7 co-infection (“CMV viral syndrome”) 45 days prior rejection. Two patients 
that had co-infection before graft rejection were accompanied with persistent liver 
dysfunction until rejection episode. Another two patients had only HHV-6 infection 
accompanied with thrombocytopenia and leukopenia were related with rejection 
episodes. Unfortunately, we were not able to perform viral antigens detection in liver 
biopsies. In patients who had liver dysfunction and/or graft rejection, no underlying liver 
disease (HCV or HBV) were relapsed until end of the monitoring (180 days) and no other 
infectious agent was found. Only one case of “CMV viral syndrome” was recurrent and 
occurred after graft rejection.  
Two episodes of pneumonitis were related with HHV-6/HHV-7 co-infection. One case of 
pneumonitis and two of encephalitis were also related with only HHV-6 infection and no 
others infectious agents were found. However, other tests to detect HHV-6 and HHV-7 in 
tissue samples might not be performed. In CMV and HHV-6 free patients no symptoms or 
significant laboratorial findings could be related to HHV-7.  
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Fig. 3. Venn diagrams illustrating the number of patients (n=29) or number of positive 
samples (n=198) that were positive nested-PCR for any combination of betaherpesviruses 
4. Discussion 
The high frequency of positive IgG test against CMV observed agrees with previously data 
indicating a prevalence of 90 to 100% anti-CMV antibodies in Brazilian population 
(Suassuna et al., 1995; Costa et al., 1999). Previously studies in Brazilian population have 
also demonstrated high prevalence of HHV-6 and HHV-7 (90 and 84%, respectively).  
CMV, HHV-6 and HHV-7 were frequently detected in patients after liver transplant (68.9%, 
44.8% and 48.2%, respectively). Ihira et al. (2001) and Feldstein et al. (2003) suggested that 
the detection of virus DNA in serum by PCR is a useful marker of HHV-6 and HHV-7 active 
infection. In adult liver transplant recipients, Griffths et al. (1999) found CMV DNA in 47%, 
HHV-6 DNA in 32% and HHV-7 DNA in 48% of the patients. Ihira et al. (2001) found HHV-
6 DNA in 38% and HHV-7 DNA in 40% of the patients until 8 weeks after liver 
transplantation. Humar et al. (2000) found CMV DNA in 63.6% and HHV-6 DNA in 54.5% 
of the liver transplant recipients.  
The rate difference in each report depends of the sensitivity of PCR, type of transplantation, 
immunosuppressive protocol, the size of samples used and differences among subjects. 
However, the rate found in this study was relatively similar with others reports. Interesting, 
6/29 (20.7%) patients had positive detectable HHV-7 DNA at the time of transplantation 
without symptoms. In addition, IgM against HHV-7 was found in all samples contributing 
to the hypothesis of true active infection had occurred. Since that this method did not detect 
latent infection in previously study (Thomasini et al., 2008) and blood was collected before 
surgery, it could be explained by reactivation caused by underlying liver disease or by 
transient viremia. Although some syndromes related to HHV-7 in immunocompetent 
patients have been described (Ward et al., 2005), studies in pre-transplant time should be 
performed to evaluate each hypothesis. 
Ten of twelve (50%) patients who had detectable CMV DNA developed symptomatic CMV 
infection. The remaining 10 patients without symptoms could be explained by the high 
sensibility of the PCR, that can detect lower viral load (Tokimatsu et al.,1995), and they were 
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not treated. However, the statistical analysis showed correlation between detection of CMV 
DNA and symptomatic CMV infection. Our symptomatic CMV incidence (34.4%) was 
higher (1.54-fold) than incidence reported by Humar et al. (2000) that reported symptomatic 
CMV infection in 21.6% of the patients. Similar to this study, Härmä et al. (2006) found 30% 
of symptomatic CMV infection during 3 first months after transplantation.  
We have considered that this higher incidence of CMV infection and symptomatic CMV 
infection due to high prevalence of CMV in Brazilian population, no routine or preemptive 
ganciclovir therapy and use of cyclosporine. Humar et al. (2000) have found an 
independently increasing risk factor for development of CMV disease when patient had 
D+/R+ CMV serostatus and all patients enrolled in this study were D+/R+. It is conflicting 
with most reports that suggest higher risk factor when CMV serostatus is D+/R-. Hoppe et 
al. (2004) had suggests a higher probability of CMV infection among patients treated with 
cyclosporine compared to tracolimus.  
Some cases of pneumonitis and encephalitis were related to HHV-6 active infection or with 
co-infections HHV-6/HHV-7. Previously reports had suggested association an increase risk 
of graft rejection associated with CMV (Lautenschlager et al., 1997). Although we have 
found that symptomatic CMV infection was present in most cases of liver dysfunction and 
graft rejection, CMV co-infection with HHV-6 or HHV-7 and HHV-6 alone were more likely 
related with graft rejection than CMV alone. Härmä et al. (2006) had suggested a role of 
HHV-6 in liver dysfunction and graft rejection (with HHV-6 antigens detected in liver 
biopsies in same patients). Griffiths et al. (1999) found also association between liver 
dysfunction and graft rejection with HHV-6 and dysfunction with HHV-7. HHV-6 could 
either be participating directly in the rejection process or potentially exacerbating the 
inflammatory response characteristic of rejection (Emery, 2001). However, the fact that the 
most of patients with HHV-6 active infection were asymptomatic in this study (probably 
due to transient viremia) turned difficult to establish a relation between liver 
dysfunction/graft rejections with HHV-6 active infection. In addition, all of the positive 
patients included in this study have betaherpesviruses reactivation/reinfection and not 
primary infection. Betaherpesviruses primary infections could have more significant clinical 
outcomes and this hypothesis should be considered in pediatric liver transplantation which 
primary infections could be more frequent.  
In CMV and HHV-6 free patients no symptoms or significant laboratorial findings could be 
related to HHV-7. However, the role of the HHV-7 in down regulation of CD4 expression in 
lymphocytes has been described (Secchiero et al., 1997; Secchiero et al., 1998) and a possible 
immnunomodulatory effects do not be discarded. Studies regarding CMV, HHV-6 and 
HHV-7 including determination of viral load with ‘cut-off’ values for clinical manifestation 
and detection of viral antigens in liver biopsies as well as evaluation of cellular and humoral 
immune response could be performed. In this study we have considered qualitative nested-
PCR which had limited value for clinical monitoring of the betaherpesvirus. 
5. Conclusion 
The results described above show that few patients remain free of betaherpesviruses after 
liver transplantation. Most of the patients with active infection with more than one virus 
were infected sequentially and not concurrently. Active infection with HHV-6, HHV-7 or 
CMV might develop independently of one another. Most patients with HHV-6 or HHV-7 
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active infections were asymptomatic. In few patients, HHV-6 could be associated with some 
clinical manifestations and episodes of graft dysfunction and rejection. Qualitative nested-
PCR was considered of limited value to clinical monitoring of betaherpesviruses.  
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